Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: A longitudinal analysis

Clinical Infectious Diseases

Volumn 57, Issue 6, 2013, Pages 828-835

  Al Shair, Khaled ^a,b   Atherton, Graham T ^a   Harris, Christine ^a   Ratcliffe, Libuse ^a   Newton, Philippa J ^a   Denning, David W ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b HADHRAMOUT UNIVERSITY   (Yemen)

Author keywords

Aspergillus fumigatus; dyspnea; itraconazole; posaconazole; voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ANKLE EDEMA; ANTIMICROBIAL THERAPY; ARTICLE; BODY MASS; CHRONIC DRUG ADMINISTRATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; LUNG ASPERGILLOSIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

ASPERGILLUS FUMIGATUS; DYSPNEA; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

AGED; ANTIFUNGAL AGENTS; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PULMONARY ASPERGILLOSIS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84881555596     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit411     Document Type: Article

References (35)

1. Denning DW, Riniotis K, Dobrashian R, Sambatakou H. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37(suppl 3):S265-80.
2. Camuset J, Nunes H, Dombret MC, et al. Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 2007; 131:1435-41.
3. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123-9.
4. Saraceno JL, Phelps DT, Ferro TJ, Futerfas R, Schwartz DB. Chronic necrotizing pulmonary aspergillosis: approach to management. Chest 1997; 112:541-8.
5. Pendleton M, Denning DW. Multifocal pulmonary aspergillomas-a management challenge. NY Acad Sci 2012; 1272:58-67.
6. Baxter CG, Bishop P, Low SE, Baiden-Amissah K, Denning DW. Pulmonary aspergillosis: an alternative diagnosis to lung cancer after positive [18F]FDG positron emission tomography. Thorax 2011; 66:638-40.
7. Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax 1983; 38:572-8.
8. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14:e479-82.
9. Tomlinson JR, Sahn SA. Aspergilloma in sarcoid and tuberculosis. Chest 1987; 92:505-8.
10. Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010; 51:1383-91.
11. Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012; 31:3231-9.
12. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990; 23(3 Pt 2):607-14.
13. Agarwal R, Vishwanath G, Aggarwal AN, Garg M, Gupta D, Chakrabarti A. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; doi: 10.1111/myc.12075.
14. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-7.
15. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-9.
16. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4:CD008989.
17. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140:68-75.
18. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19:398-404.
19. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156(2 Pt 1):536-41.
20. Padilla A, Olveira G, Olveira C, et al. Validity and reliability of the St George's Respiratory Questionnaire in adults with cystic fibrosis. Arch Bronconeumol 2007; 43:205-11.
21. Pasipanodya JG, Miller TL, Vecino M, et al. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 2007; 132:1591-8.
22. Al-shair K, Atherton GT, Kennedy D, Powell G, Denning DW, Caress A. Validity and reliability of the St. George's Respiratory Questionnaire in assessing health status in patients with chronic pulmonary aspergillosis. Chest 2012. doi:10.1378/chest.12-0014.
23. Harrison E, Singh A, Morris J, et al. Mannose binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet 2012; 39:224-32.
24. Kohno S, Izumikawa K, Kakeya H, et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011; 49:688-93.
25. Sambatakou H, Dupont B, Lode H, Denning DW. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006; 119:527 e17-24.
26. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005; 2:75-9.
27. Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 2012; 40:661-7.
28. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 55: 1080-7.
29. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-40.
30. Chishimba L, Niven RM, Cooley J, Denning DW. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma 2012; 49:423-33.
31. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science 2012; 336:647.
32. Make B. How can we assess outcomes of clinical trials: the MCID approach. COPD 2007; 4:191-4.
33. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2011; 52(suppl 4):S290-5.
34. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38.
35. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179:11-8.